{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:24:54Z","timestamp":1789655094542,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-acting injectable (LAI) antipsychotics improve adherence and reduce schizophrenia relapse rates vs oral antipsychotics (OAs) but remain underused. The ADVANCE study explored country-level differences in LAI use among healthcare professionals (HCPs), patients, and caregivers, to identify drivers of LAI use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>ADVANCE included participants from Australia, Canada, China, Germany, Israel, South Korea, Spain, and the United States. Eligible HCPs spent \u226525% of their time in direct patient care, managed an adult population of whom \u226510% have schizophrenia, and treated patients prescribed LAIs. Patients aged \u226518\u00a0years and caregivers of adults living with schizophrenia who had tried\/been offered an LAI were included. Participants completed a 30-minute survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Systemic factors reported by HCPs (n\u2009=\u2009791) associated with higher LAI use included being a physician vs nonphysician, having Hispanic\/Latino\/Spanish ethnicity, managing more adult patients with schizophrenia, and having more staff and nurse support. Nonadherence to OAs was the main HCP-reported reason for LAI recommendation. Patient characteristics, lack of available LAIs corresponding to OAs, and perceptions of patients\u2019 behavior were top reasons HCPs would not recommend an LAI. For patients (n\u2009=\u2009470), symptom improvement and HCP recommendation, and for caregivers (n\u2009=\u2009381), ease of injections, reduced hospitalizations, and fewer side effects were the main reasons for LAI acceptance. The top reason patients and caregivers declined LAIs was concern about side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results from ADVANCE demonstrate that systemic and attitudinal factors influence LAI use by HCPs, and these factors vary by country. Enhancing HCP-patient communication may improve LAI acceptance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgaf032","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:48:36Z","timestamp":1765889316000},"source":"Crossref","is-referenced-by-count":3,"title":["Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study"],"prefix":"10.1093","volume":"7","author":[{"given":"Kelli R","family":"Franzenburg","sequence":"first","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC, Global Medical Affairs , West Chester, PA 19380 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC, North America Medical Affairs , Parsippany, NJ 07054 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[{"name":"Teva UK Limited, Global Medical Affairs , Harlow CM20 2FB ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Yaari","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd., Global Medical Affairs , Tel Aviv 6944020 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Peyser Levin","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd., International Markets Medical Affairs , Tel Aviv 6944020 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sergerie","sequence":"additional","affiliation":[{"name":"Teva Canada, Medical Affairs, Montreal , QC H2Z 1S8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd., Global Health Economics and Outcome Research , Netanya 4250483 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameron","family":"Sedigh","sequence":"additional","affiliation":[{"name":"Syneos Health Consulting , New York, NY 10281 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[{"name":"kbo-Klinik f\u00fcr Psychiatrie und Psychotherapie Nord , 80804 M\u00fcnchen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sajatovic","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026012802460140000_ref1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026012802460140000_ref2","doi-asserted-by":"publisher","first-page":"e2224163","DOI":"10.1001\/jamanetworkopen.2022.24163","article-title":"Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia","volume":"5","author":"Wei","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026012802460140000_ref3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12888-021-03037-0","article-title":"Daily functioning and symptom factors contributing to attitudes toward Antipsychotic treatment and treatment adherence in outpatients with schizophrenia Spectrum disorders","volume":"21","author":"Leijala","year":"2021","journal-title":"BMC Psychiatry"},{"key":"2026012802460140000_ref4","doi-asserted-by":"publisher","first-page":"IN18031AH1C","DOI":"10.4088\/JCP.IN18031AH1C","article-title":"Optimizing treatment choices to improve adherence and outcomes in schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2026012802460140000_ref5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with Antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Related Outcome Measures"},{"key":"2026012802460140000_ref6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","article-title":"Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners","volume":"12","author":"Schwartz","year":"2022","journal-title":"Ment Health Clin"},{"key":"2026012802460140000_ref7","doi-asserted-by":"publisher","first-page":"18m12546","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2026012802460140000_ref8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/schbul\/sbad089","article-title":"Long-acting injectable second-generation antipsychotics vs placebo and their oral formulations in acute schizophrenia: a systematic review and meta-analysis of randomized-controlled-trials","volume":"50","author":"Wang","year":"2024","journal-title":"Schizophr Bull"},{"key":"2026012802460140000_ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"2026012802460140000_ref10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr Res"},{"key":"2026012802460140000_ref11","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","article-title":"Long-term continuity of antipsychotic treatment for schizophrenia: a Nationwide study","volume":"47","author":"Rubio","year":"2021","journal-title":"Schizophr Bull"},{"key":"2026012802460140000_ref12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5080\/u27551","article-title":"\u015eizofrenide Uzun Etkili Enjektabl Antipsikotik Tedaviye Ge\u00e7i\u015fin Bak\u0131m Y\u00fck\u00fc \u00dczerine Etkisi","volume":"13","author":"Tozo\u011flu","year":"2021","journal-title":"Psikiyatride G\u00fcncel Yakla\u015f\u0131mlar"},{"key":"2026012802460140000_ref13","doi-asserted-by":"publisher","first-page":"770276","DOI":"10.3389\/fpubh.2021.770276","article-title":"Attitudes and willingness to accept long-acting injections for patients with schizophrenia in Beijing: a cross-sectional investigation based on samples from the communities","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Public Health"},{"key":"2026012802460140000_ref14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/07067437211055413","article-title":"Real-world utilization patterns of long-acting injectable antipsychotics in Canada: a retrospective study","volume":"67","author":"Agid","year":"2022","journal-title":"Can J Psychiatr"},{"key":"2026012802460140000_ref15","doi-asserted-by":"publisher","first-page":"e12393","DOI":"10.1111\/appy.12393","article-title":"Patterns of long acting injectable Antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and regions","volume":"12","author":"Tang","year":"2020","journal-title":"Asia Pac Psychiatry"},{"key":"2026012802460140000_ref16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/jpm12030441","article-title":"Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric Hospital in Switzerland","volume":"12","author":"Reymann","year":"2022","journal-title":"J Pers Med"},{"key":"2026012802460140000_ref17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"key":"2026012802460140000_ref18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12888-025-06565-1","article-title":"Clinician differences in attitudes and perceptions on the use of long-acting injectable Antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey","volume":"25","author":"Velligan","year":"2025","journal-title":"BMC Psychiatry"},{"key":"2026012802460140000_ref19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/npr2.12435","article-title":"Barriers to long-acting injectable atypical Antipsychotic use in Japan: Insights from a comparative psychiatrist survey","volume":"44","author":"Oguchi","year":"2024","journal-title":"Neuropsychopharmacol Rep"},{"key":"2026012802460140000_ref20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/JCP.0000000000001225","article-title":"Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"40","author":"Lindenmayer","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"2026012802460140000_ref21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","article-title":"Barriers to the use of long-acting injectable antipsychotics in the Management of Schizophrenia","volume":"30","author":"Parellada","year":"2016","journal-title":"CNS Drugs"},{"key":"2026012802460140000_ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1645328","article-title":"Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study","volume":"16","author":"Frazenburg","year":"2025","journal-title":"Frontiers in Psychiatry"},{"key":"2026012802460140000_ref23","first-page":"2024","author":"Association EPMR","year":"2024"},{"key":"2026012802460140000_ref24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2026012802460140000_ref25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/NDT.S369494","article-title":"Understanding the health system conditions affecting the use of long-acting injectable antipsychotics in the treatment of schizophrenia in clinical practice: a US healthcare provider survey","volume":"18","author":"Zhdanava","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026012802460140000_ref26","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2147\/PPA.S410028","article-title":"Switching from monthly to three-monthly long-acting injectable paliperidone: a survey on subjective satisfaction and safety","volume":"17","author":"Barnett","year":"2023","journal-title":"Patient Preference and Adherence"},{"key":"2026012802460140000_ref27","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.3390\/jcm12226985","article-title":"Second generation long-acting injectable antipsychotics in schizophrenia: the patient's subjective quality of life, well-being, and satisfaction","volume":"12","author":"Brasso","year":"2023","journal-title":"J Clin Med"},{"key":"2026012802460140000_ref28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2147\/PPA.S520160","article-title":"Exploring patient, caregiver, and prescriber preferences for an injectable Antipsychotic administered every 2 months for the maintenance treatment of schizophrenia: a multicenter qualitative interview study conducted in Europe","volume":"19","author":"Pappa","year":"2025","journal-title":"Patient Preference and Adherence"},{"key":"2026012802460140000_ref29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Efficacy, acceptability and side-effects of oral versus long-acting injectable antipsychotics: systematic review and network meta-analysis","volume":"83","author":"Wang","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026012802460140000_ref30","doi-asserted-by":"publisher","first-page":"e0276814","DOI":"10.1371\/journal.pone.0276814","article-title":"Prevalence, causes, impacts, and Management of Needle Phobia: an international survey of a general adult population","volume":"17","author":"Alsbrooks","year":"2022","journal-title":"PLoS One"},{"key":"2026012802460140000_ref31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.schres.2024.10.006","article-title":"The effectiveness of peer support on the recovery and empowerment of people with schizophrenia: a systematic review and meta-analysis","volume":"274","author":"Jambawo","year":"2024","journal-title":"Schizophr Res"},{"key":"2026012802460140000_ref32","doi-asserted-by":"publisher","first-page":"sgaf001","DOI":"10.1093\/schizbullopen\/sgaf001","article-title":"Preferences for selecting and initiating long-acting injectable Antipsychotic agents for the treatment of patients with schizophrenia: results from the US DECIDE survey","volume":"6","author":"Velligan","year":"2025","journal-title":"Schizophr Bull Open"},{"key":"2026012802460140000_ref33","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","article-title":"Patient and healthcare professional preferences for characteristics of long-acting injectable Antipsychotic agents for the treatment of schizophrenia","volume":"40","author":"Robinson","year":"2023","journal-title":"Adv Ther"}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgaf032\/65921829\/sgaf032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgaf032\/65921829\/sgaf032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgaf032\/65921829\/sgaf032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:46:07Z","timestamp":1769586367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgaf032\/8381442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgaf032","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,16]]},"article-number":"sgaf032"}}